RxDoctor Payments Data

Fayez Siddiqui, MD

Interventional Cardiology · Mason City, IANPI 1366797755

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.4%), grants and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 70.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $8,288 and has fallen 78.3% since, to $1,801 in 2025.

$20,709in general payments, 2019–2025

Across 229 payments — averaging $90.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Terumo Medical Corporation$2K
  • Boston Scientific$1K
  • Abbott$1K
  • Edwards Lifesciences$874
  • Abiomed$494
  • plus $455 from 10 others

What the payments were for

  • Grants$6,50031%
  • Travel & lodging$7,53836%
  • Food & beverage$6,36931%
  • Education$3021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,709 in reported general payments places this provider in the 80th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$194,847
Medicare patients
908
Services billed
2,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$32,426
XareltoRivaroxaban21$21,629
Praluent PenAlirocumab12$6,099
Metoprolol Succinate183$2,211
Isosorbide Mononitrate ErIsosorbide Mononitrate66$853
Atorvastatin Calcium120$830
ClopidogrelClopidogrel Bisulfate60$504
Pantoprazole Sodium28$451
Losartan Potassium60$440
Chlorthalidone18$407
Cilostazol26$403
Lisinopril66$380
Amlodipine Besylate64$297
Carvedilol46$286
Rosuvastatin Calcium33$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$32,42636 claims
Johnson & JohnsonXarelto$15$21,62921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →